This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen's TDM-1 Looks Strong at ESMO

Updates with recent stock price.

BOSTON ( TheStreet) -- The "armed antibody" drug TDM-1 under development by Roche and ImmunoGen (IMGN - Get Report) posted a higher response rate and lower toxicity than the blockbuster breast cancer drug Herceptin, according to results from the first head-to-head study of the two drugs to be presented at a European cancer meeting Monday.

The data from the TDM-1 phase II study in front-line breast cancer patients are early and very preliminary, but also encouraging because they suggest TDM-1 may be the next-generation successor to Herceptin that Roche has been looking for.

ImmunoGen, as Roche's partner on TDM-1, stands to profit as well if the drug is approved and successful.

In the phase II study, 137 women with HER2-positive metastatic breast cancer with no prior chemotherapy were randomly assigned to treatment with TDM-1 or Herceptin plus the chemotherapy drug Taxotere.

After six months of follow-up, the overall response rate for patients treated with TDM-1 was 48% compared to a 41% response rate for patients treated with Herceptin-Taxotere.

More striking was the difference in the rate of adverse events between the two drugs. The rate of "clinically relevant" adverse events (defined as Grade 3 or higher) was 37% in the TDM-1 arm compared to 75% in the Herceptin-Taxotere arm.

A full presentation of the T-DM1 study will be made Monday at the European Society of Medical Oncology (ESMO) annual meeting taking place in Milan.

Roche CEO Severin Schwan called the TDM-1 data "stunning" at a press event in Tokyo, according to a Reuters story Friday.

ImmunoGen shares were up 6% to $7.09 in late Friday trading.

T-DM1 is a so-called "armed antibody" that combines the targeted antibody drug Herceptin owned by Roche (already a potent cancer drug on its own) with a chemotherapy payload developed by ImmunoGen.

TDM-1 is designed to deliver a cancer-killing dose of chemotherapy directly inside tumors, sparring healthy cells from toxic side effects. This may explain the sharply lower toxicities observed in the front-line breast cancer study of TDM-1 compared to Herceptin-Taxotere.

For instance, the rates of hair loss and neutropenia (low white blood cell counts) in the Herceptin-Taxotere arm were 66% and 57%, respectively. By comparison, hair loss and neutropenia were reported in 1.5% and 7.5% of TDM-1 patients, respectively.

More patients treated with TDM-1 reported fever and nausea than those treated with Herceptin-Taxotere.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMGN $7.18 0.84%
AAPL $95.06 0.05%
FB $99.79 0.04%
GOOG $679.66 -0.45%
TSLA $149.27 0.86%


Chart of I:DJI
DOW 16,042.90 +15.85 0.10%
S&P 500 1,864.02 +10.58 0.57%
NASDAQ 4,308.1360 +24.3830 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs